Company Overview and News

22
5 Turnaround Stocks to Buy Now

2018-10-17 investorplace
U.S. equities surged higher on Tuesday, aided by a positive outlook from Adobe (NASDAQ:ADBE) overnight. Traders focused in on extremely strong jobs data, with the JOLTS report showing more than seven million openings for the first time ever. Moreover, there are now more than a million more job openings than unemployed persons.
HMY AULGF EAT SJM TWTR AU AGG HGMCF ADBE

1
Renaissance Gold Exploration Update

2018-10-17 accesswire
VANCOUVER, BC / ACCESSWIRE / October 17, 2018 / Renaissance Gold Inc. (TSX.V: REN / OTCQB: RNSGF) ("RenGold" or the "Company") is pleased to report on the progress and status of its Nevada, USA projects and our anticipated drilling plans for the remainder of 2018. The location of RenGold's properties is shown in Figure 1.
AULGF RNSGF RMS REN RDUFF AU AGG S2R RDU RMLRF

1
AngloGold Ashanti (AU) Shares March Higher, Can It Continue?

2018-10-12 zacks
As of late, it has definitely been a great time to be an investor in AngloGold Ashanti Limited (AU - Free Report) . The stock has moved higher by 20.9% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
AULGF AU AGG

1
RPT-UPDATE 1-Court says Colombia votes cannot block mining, oil projects

2018-10-12 reuters
BOGOTA, Oct 11 (Reuters) - Colombia’s constitutional court on Thursday ruled that local referendums that ban mining and oil extraction cannot halt energy projects, after a raft of votes spooked multinational companies.
AULGF AU AGG

1
Franco-Nevada (FNV) Catches Eye: Stock Jumps 7.2%

2018-10-12 zacks
Franco-Nevada Corporation (FNV - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $61.49 to $65.29 in the past one-month time frame. The company has seen one negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road.
AULGF AU AGG FNV

1
UPDATE 1-Court says Colombia votes cannot block mining, oil projects

2018-10-12 reuters
BOGOTA (Reuters) - Colombia’s constitutional court on Thursday ruled that local referendums that ban mining and oil extraction cannot halt energy projects, after a raft of votes spooked multinational companies.
AULGF AU AGG

1
Boart Longyear: Engineering ideas

2018-10-10 australianmining.com.au
Boart Longyear’s global engineering and drilling services teams are uniquely intertwined. Australian Mining finds out what the company’s approach brings to drilling innovation.
AULGF NST BLY AU AGG NHRNY NESRF

1
Companies launch programs to battle mental health stigma

2018-10-10 australianmining.com.au
World Mental Health Day has seen the successful roll out of a ‘gamified microlearning’ program for miners to combat stigma around mental health.
AULGF AU AGG

1
Harmony Gold: Wage Deal Will Bear Fruit For The Company In The Long Term.

2018-10-09 seekingalpha
The future outlook of HMY looks stronger with stability of operations, increased gold production, healthy grades and improving gold prices.
AULGF AU AGG

1
Randgold Resources Limited Announces Morila's Agribusiness Project Gets Govt Go-ahead

2018-10-08 accesswire
JERSEY, CHANNEL ISLANDS / ACCESSWIRE / October 8, 2018 / RANDGOLD RESOURCES LIMITED (LSE: RRS; NASDAQ: GOLD)
AULGF RGORF AU AGG GOLD RRS GOLD

1
Mali expects 2018 industrial gold output to rise 21 pct

2018-10-05 reuters
BAMAKO, Oct 5 (Reuters) - Industrial gold production in Mali, Africa’s third biggest producer, is still expected to rise almost 21 percent to 60 tonnes this year, a government official told Reuters on Friday, despite slightly lower than expected output so far.
AULGF RSG RMGGY HUMRF RGORF RMGGF AU AGG GOLD RRS HUM GOLD

4
Drill Targets Defined at Lakanfla Gold Project, Western Mali

2018-10-02 accesswire
NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES NOR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA
AULGF AU AGG IMG IAG

2
Gold's Junior Miners Set To Outperform?

2018-09-29 seekingalpha - 1
But macro factors suggest trend reversal, as consumer inflation is rising, and markets are looking for an alternative store of value.
AULGF EVN NST AU CAHPF AGG NHRNY GDXJ NESRF

1
UPDATE 2-Randgold faces pushback from Congo over Barrick takeover of Kibali mine

2018-09-28 reuters
DAKAR (Reuters) - Randgold Resources Ltd has run into opposition from the Democratic Republic of Congo’s government, which is insisting that it authorize the acquisition by Canada’s Barrick Gold Corp of Randgold’s stake in a Congolese gold mine.
AULGF ABX RGORF AU 3993 AGG GOLD RRS GOLD ABX

1
Congo mines minister backs state miner over Barrick's Kibali takeover

2018-09-28 reuters
DAKAR, Sept 28 (Reuters) - Barrick Gold Corp’s acquisition of Randgold’s stake in the Kibali gold mine requires approval by the Democratic Republic of Congo’s government, Mines Minister Martin Kabwelulu said on Friday.
AULGF ABX AU AGG ABX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...